FindTrial
Sign In

LBL-024 for Injection

DRUG11 trials

Sponsors

Nanjing Leads Biolabs Co.,Ltd

Conditions

Advanced Extrapulmonary Neuroendocrine CarcinomaAdvanced MelanomaAdvanced Neuroendocrine CarcinomaAdvanced Solid TumorAdvanced Solid TumourMetastatic Colorectal CarcinomaOvarian CancerTriple Negative Breast Cancer

Phase 1

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
RecruitingNCT05170958
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumor
Start: 2022-01-06End: 2026-12-01Target: 396Updated: 2026-06-30
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
RecruitingNCT06157827
Nanjing Leads Biolabs Co.,LtdAdvanced Neuroendocrine Carcinoma
Start: 2023-12-08End: 2027-03-28Target: 178Updated: 2026-03-12
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
RecruitingNCT07042802
Nanjing Leads Biolabs Co.,LtdOvarian Cancer
Start: 2025-12-02End: 2028-12-25Target: 180Updated: 2026-08-13
A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
RecruitingNCT07099430
Nanjing Leads Biolabs Co.,LtdAdvanced Melanoma
Start: 2025-09-05End: 2027-12-30Target: 200Updated: 2026-05-18
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
RecruitingNCT07281976
Nanjing Leads Biolabs Co.,LtdTriple Negative Breast Cancer
Start: 2026-01-27End: 2027-12-31Target: 220Updated: 2026-02-12
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
Not yet recruitingNCT07791758
Nanjing Leads Biolabs Co.,LtdMetastatic Colorectal Carcinoma
Start: 2026-09-04End: 2030-09-04Target: 369Updated: 2026-09-02

Phase 2

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
RecruitingNCT06783647
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2025-06-11End: 2026-12-24Target: 250Updated: 2026-08-27
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
RecruitingNCT07111546
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2025-10-20End: 2027-12-26Target: 140Updated: 2026-08-31
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
RecruitingNCT07331155
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2026-02-26End: 2028-12-26Target: 110Updated: 2026-05-18
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
RecruitingNCT07390383
Nanjing Leads Biolabs Co.,LtdAdvanced Solid Tumour
Start: 2026-04-13End: 2028-05-30Target: 110Updated: 2026-05-13

Phase 3

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Not yet recruitingNCT07720193
Nanjing Leads Biolabs Co.,LtdAdvanced Extrapulmonary Neuroendocrine Carcinoma
Start: 2026-08-22End: 2030-12-22Target: 280Updated: 2026-09-01

Related Papers

Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
Journal of Clinical Oncology2025-05-28
A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.
Journal of Clinical Oncology2024-06-011 citations